Meeting
2019 ASCO Annual Meeting
Real-life data: Women with recurrent platinum-sensitive ovarian cancer and BCARGEM treatment.
Authors
Frederique C. van der Scheun
Department of Medical Oncology, Cancer Center University Medical Center Utrecht, University of Utrecht, Utrecht, Netherlands
Frederique C. van der Scheun , Cheryl P. Bruijnen , Petronella Witteveen , Britt B.M. Suelmann
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Citation
J Clin Oncol 37, 2019 (suppl; abstr 5566)
DOI
10.1200/JCO.2019.37.15_suppl.5566
Abstract #
5566
Poster Bd #
389
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
An updated safety analysis of OCEANS, a randomized, double-blind, phase III trial of gemcitabine (G) and carboplatin (C) with bevacizumab (BV) or placebo (PL) followed by BV or PL to disease progression (PD) in patients with platinum-sensitive (Plat-S) recurrent ovarian cancer.
First Author: Carol Aghajanian
Poster
2022 ASCO Annual Meeting
Efficacy and toxicity of carboplatin and gemcitabine dosed on day 1/day 8 versus day 1 alone for platinum-sensitive recurrent epithelial ovarian cancer.
First Author: Erika Joelle Lampert
Poster
2021 ASCO Annual Meeting
Postoperative adjuvant dose-dense chemotherapy with bevacizumab and maintenance bevacizumab after neoadjuvant chemotherapy for advanced ovarian cancer: A phase II AGOG/TGOG trial.
First Author: Wei-Chun Chen
Poster
2021 ASCO Annual Meeting
Institutional experience with nab-sirolimus in patients with malignancies harboring TSC1 or TSC2 mutations.
First Author: Mark Andrew Dickson